APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Vaccine for Tumor

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Peptide Vaccine for Tumor Industry Growth and Trends Forecast to 2032

27 December 202597 pages

Choose your research edition.

Industry ResearchPeptide Vaccine for Tumor Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Vaccine for Tumor Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Peptide Vaccine for Tumor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Vaccine for Tumor Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Vaccine for Tumor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peptide Vaccine for Tumor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide Vaccine for Tumor include AmbioPharm, Ultimovacs, Sellas Life Sciences, OncoPep, Marker Therapeutics, Inc., Immatics, Anergis, Almac and ACT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Peptide Vaccine for Tumor market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Peptide Vaccine for Tumor market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Peptide Vaccine for Tumor market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Peptide Vaccine for Tumor.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Peptide Vaccine for Tumor market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Peptide Vaccine for Tumor Market by Company

AmbioPharm

Ultimovacs

Sellas Life Sciences

OncoPep

Marker Therapeutics, Inc.

Immatics

Anergis

Almac

ACT

Peptide Vaccine for Tumor Segment by Type

Recombinant Polypeptide Vaccine

Synthetic Polypeptide Vaccines

Others

Peptide Vaccine for Tumor Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Others

Peptide Vaccine for Tumor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Vaccine for Tumor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Vaccine for Tumor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Vaccine for Tumor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide Vaccine for Tumor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Peptide Vaccine for Tumor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Recombinant Polypeptide Vaccine Table 2. Major Company of Synthetic Polypeptide Vaccines Table 3. Major Company of Others Table 4. Global Peptide Vaccine for Tumor Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Units) Table 6. Global Peptide Vaccine for Tumor Sales Market Share in Volume by Type (2021-2026) Table 7. Global Peptide Vaccine for Tumor Sales by Type (2021-2026) & (US$ Million) Table 8. Global Peptide Vaccine for Tumor Sales Market Share in Value by Type (2021-2026) Table 9. Global Peptide Vaccine for Tumor Price by Type (2021-2026) & (US$/Unit) Table 10. Global Peptide Vaccine for Tumor Sales by Type (2027-2032) & (K Units) Table 11. Global Peptide Vaccine for Tumor Sales Market Share in Volume by Type (2027-2032) Table 12. Global Peptide Vaccine for Tumor Sales by Type (2027-2032) & (US$ Million) Table 13. Global Peptide Vaccine for Tumor Sales Market Share in Value by Type (2027-2032) Table 14. Global Peptide Vaccine for Tumor Price by Type (2027-2032) & (US$/Unit) Table 15. North America Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Units) Table 16. North America Peptide Vaccine for Tumor Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Units) Table 18. Europe Peptide Vaccine for Tumor Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Peptide Vaccine for Tumor Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Units) Table 22. Latin America Peptide Vaccine for Tumor Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Peptide Vaccine for Tumor Sales by Type (2021-2026) & (US$ Million) Table 25. Peptide Vaccine for Tumor Industry Trends Table 26. Peptide Vaccine for Tumor Industry Drivers Table 27. Peptide Vaccine for Tumor Industry Opportunities and Challenges Table 28. Peptide Vaccine for Tumor Industry Restraints Table 29. Global Peptide Vaccine for Tumor Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Peptide Vaccine for Tumor Revenue Market Share by Company (2021-2026) Table 31. Global Peptide Vaccine for Tumor Sales by Company (2021-2026) & (K Units) Table 32. Global Peptide Vaccine for Tumor Sales Share by Company (2021-2026) Table 33. Global Peptide Vaccine for Tumor Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Peptide Vaccine for Tumor Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Peptide Vaccine for Tumor Major Company Production Sites and Headquarters Table 36. Global Peptide Vaccine for Tumor Company, Product Type & Application Table 37. Global Peptide Vaccine for Tumor Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Peptide Vaccine for Tumor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Peptide Vaccine for Tumor Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Peptide Vaccine for Tumor Sales by Region (2021-2026) & (K Units) Table 42. Global Peptide Vaccine for Tumor Sales Market Share in Volume by Region (2021-2026) Table 43. Global Peptide Vaccine for Tumor Sales by Region (2021-2026) & (US$ Million) Table 44. Global Peptide Vaccine for Tumor Sales Market Share in Value by Region (2021-2026) Table 45. Global Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Peptide Vaccine for Tumor Sales by Region (2027-2032) & (K Units) Table 47. Global Peptide Vaccine for Tumor Sales Market Share in Volume by Region (2027-2032) Table 48. Global Peptide Vaccine for Tumor Sales by Region (2027-2032) & (US$ Million) Table 49. Global Peptide Vaccine for Tumor Sales Market Share in Value by Region (2027-2032) Table 50. Global Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Peptide Vaccine for Tumor Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Units) Table 53. Global Peptide Vaccine for Tumor Sales Market Share in Volume by Application (2021-2026) Table 54. Global Peptide Vaccine for Tumor Sales by Application (2021-2026) & (US$ Million) Table 55. Global Peptide Vaccine for Tumor Sales Market Share in Value by Application (2021-2026) Table 56. Global Peptide Vaccine for Tumor Price by Application (2021-2026) & (US$/Unit) Table 57. Global Peptide Vaccine for Tumor Sales by Application (2027-2032) & (K Units) Table 58. Global Peptide Vaccine for Tumor Sales Market Share in Volume by Application (2027-2032) Table 59. Global Peptide Vaccine for Tumor Sales by Application (2027-2032) & (US$ Million) Table 60. Global Peptide Vaccine for Tumor Sales Market Share in Value by Application (2027-2032) Table 61. Global Peptide Vaccine for Tumor Price by Application (2027-2032) & (US$/Unit) Table 62. North America Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Units) Table 63. North America Peptide Vaccine for Tumor Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Units) Table 65. Europe Peptide Vaccine for Tumor Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Peptide Vaccine for Tumor Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Units) Table 69. Latin America Peptide Vaccine for Tumor Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Peptide Vaccine for Tumor Sales by Application (2021-2026) & (US$ Million) Table 72. AmbioPharm Company Information Table 73. AmbioPharm Business Overview Table 74. AmbioPharm Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. AmbioPharm Peptide Vaccine for Tumor Product Portfolio Table 76. AmbioPharm Recent Development Table 77. Ultimovacs Company Information Table 78. Ultimovacs Business Overview Table 79. Ultimovacs Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Ultimovacs Peptide Vaccine for Tumor Product Portfolio Table 81. Ultimovacs Recent Development Table 82. Sellas Life Sciences Company Information Table 83. Sellas Life Sciences Business Overview Table 84. Sellas Life Sciences Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio Table 86. Sellas Life Sciences Recent Development Table 87. OncoPep Company Information Table 88. OncoPep Business Overview Table 89. OncoPep Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. OncoPep Peptide Vaccine for Tumor Product Portfolio Table 91. OncoPep Recent Development Table 92. Marker Therapeutics, Inc. Company Information Table 93. Marker Therapeutics, Inc. Business Overview Table 94. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio Table 96. Marker Therapeutics, Inc. Recent Development Table 97. Immatics Company Information Table 98. Immatics Business Overview Table 99. Immatics Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Immatics Peptide Vaccine for Tumor Product Portfolio Table 101. Immatics Recent Development Table 102. Anergis Company Information Table 103. Anergis Business Overview Table 104. Anergis Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Anergis Peptide Vaccine for Tumor Product Portfolio Table 106. Anergis Recent Development Table 107. Almac Company Information Table 108. Almac Business Overview Table 109. Almac Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Almac Peptide Vaccine for Tumor Product Portfolio Table 111. Almac Recent Development Table 112. ACT Company Information Table 113. ACT Business Overview Table 114. ACT Peptide Vaccine for Tumor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. ACT Peptide Vaccine for Tumor Product Portfolio Table 116. ACT Recent Development Table 117. North America Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 118. North America Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 119. North America Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026) Table 120. North America Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Units) Table 121. North America Peptide Vaccine for Tumor Sales Market Share Forecast by Country (2027-2032) Table 122. North America Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. North America Peptide Vaccine for Tumor Market Size by Country (2021-2026) & (US$ Million) Table 124. North America Peptide Vaccine for Tumor Market Share by Country (2021-2026) Table 125. North America Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. North America Peptide Vaccine for Tumor Market Share Forecast by Country (2027-2032) Table 127. Europe Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. Europe Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 129. Europe Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026) Table 130. Europe Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Units) Table 131. Europe Peptide Vaccine for Tumor Sales Market Share Forecast by Country (2027-2032) Table 132. Europe Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Europe Peptide Vaccine for Tumor Market Size by Country (2021-2026) & (US$ Million) Table 134. Europe Peptide Vaccine for Tumor Market Share by Country (2021-2026) Table 135. Europe Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Europe Peptide Vaccine for Tumor Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 139. Asia-Pacific Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026) Table 140. Asia-Pacific Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Units) Table 141. Asia-Pacific Peptide Vaccine for Tumor Sales Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Peptide Vaccine for Tumor Market Size by Country (2021-2026) & (US$ Million) Table 144. Asia-Pacific Peptide Vaccine for Tumor Market Share by Country (2021-2026) Table 145. Asia-Pacific Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Asia-Pacific Peptide Vaccine for Tumor Market Share Forecast by Country (2027-2032) Table 147. Latin America Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Latin America Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 149. Latin America Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026) Table 150. Latin America Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Units) Table 151. Latin America Peptide Vaccine for Tumor Sales Market Share Forecast by Country (2027-2032) Table 152. Latin America Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Latin America Peptide Vaccine for Tumor Market Size by Country (2021-2026) & (US$ Million) Table 154. Latin America Peptide Vaccine for Tumor Market Share by Country (2021-2026) Table 155. Latin America Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Latin America Peptide Vaccine for Tumor Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 159. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026) Table 160. Middle East and Africa Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Units) Table 161. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Peptide Vaccine for Tumor Market Size by Country (2021-2026) & (US$ Million) Table 164. Middle East and Africa Peptide Vaccine for Tumor Market Share by Country (2021-2026) Table 165. Middle East and Africa Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Middle East and Africa Peptide Vaccine for Tumor Market Share Forecast by Country (2027-2032) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Peptide Vaccine for Tumor Distributors List Table 170. Peptide Vaccine for Tumor Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Peptide Vaccine for Tumor Image Figure 2. Global Peptide Vaccine for Tumor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Vaccine for Tumor Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Vaccine for Tumor Sales (2021-2032) & (K Units) Figure 5. Recombinant Polypeptide Vaccine Image Figure 6. Global Recombinant Polypeptide Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Synthetic Polypeptide Vaccines Image Figure 8. Global Synthetic Polypeptide Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Peptide Vaccine for Tumor Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Peptide Vaccine for Tumor Market Share by Type 2025 VS 2032 Figure 13. North America Peptide Vaccine for Tumor Sales Market Share in Volume by Type in 2025 Figure 14. North America Peptide Vaccine for Tumor Sales Market Share in Value by Type in 2025 Figure 15. Europe Peptide Vaccine for Tumor Sales Market Share in Volume by Type in 2025 Figure 16. Europe Peptide Vaccine for Tumor Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Peptide Vaccine for Tumor Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Peptide Vaccine for Tumor Sales Market Share in Value by Type in 2025 Figure 19. Latin America Peptide Vaccine for Tumor Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Peptide Vaccine for Tumor Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Peptide Vaccine for Tumor Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Infectious Disease Prevention Image Figure 26. Global Infectious Disease Prevention Sales YoY Growth (2021-2032) & (K Units) Figure 27. Cancer Immunotherapy Image Figure 28. Global Cancer Immunotherapy Sales YoY Growth (2021-2032) & (K Units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Peptide Vaccine for Tumor Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Peptide Vaccine for Tumor Market Share by Application 2025 VS 2032 Figure 33. North America Peptide Vaccine for Tumor Sales Market Share in Volume by Application in 2025 Figure 34. North America Peptide Vaccine for Tumor Sales Market Share in Value by Application in 2025 Figure 35. Europe Peptide Vaccine for Tumor Sales Market Share in Volume by Application in 2025 Figure 36. Europe Peptide Vaccine for Tumor Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Peptide Vaccine for Tumor Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Peptide Vaccine for Tumor Sales Market Share in Value by Application in 2025 Figure 39. Latin America Peptide Vaccine for Tumor Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Peptide Vaccine for Tumor Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share in Value by Application in 2025 Figure 43. North America Peptide Vaccine for Tumor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Peptide Vaccine for Tumor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Peptide Vaccine for Tumor Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Peptide Vaccine for Tumor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Peptide Vaccine for Tumor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Peptide Vaccine for Tumor Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Peptide Vaccine for Tumor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Peptide Vaccine for Tumor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Peptide Vaccine for Tumor Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Peptide Vaccine for Tumor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Peptide Vaccine for Tumor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Peptide Vaccine for Tumor Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Peptide Vaccine for Tumor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Peptide Vaccine for Tumor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Peptide Vaccine for Tumor Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Peptide Vaccine for Tumor Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Peptide Vaccine for Tumor Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Polypeptide Vaccine
  • Synthetic Polypeptide Vaccines
  • Others
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Others
Companies covered
  • AmbioPharm
  • Ultimovacs
  • Sellas Life Sciences
  • OncoPep
  • Marker Therapeutics, Inc.
  • Immatics
  • Anergis
  • Almac
  • ACT

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide Vaccine for Tumor Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Peptide Vaccine for Tumor Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Peptide Vaccine for Tumor Market by Type
  6. 1.3.1 Recombinant Polypeptide Vaccine
  7. 1.3.2 Synthetic Polypeptide Vaccines
  8. 1.3.3 Others
  9. 1.4 Global Peptide Vaccine for Tumor Market Size by Type
  10. 1.4.1 Global Peptide Vaccine for Tumor Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Peptide Vaccine for Tumor Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Peptide Vaccine for Tumor Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Peptide Vaccine for Tumor Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Peptide Vaccine for Tumor Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Peptide Vaccine for Tumor Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Peptide Vaccine for Tumor Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Peptide Vaccine for Tumor Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Peptide Vaccine for Tumor Industry Trends
  2. 2.2 Peptide Vaccine for Tumor Industry Drivers
  3. 2.3 Peptide Vaccine for Tumor Industry Opportunities and Challenges
  4. 2.4 Peptide Vaccine for Tumor Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Peptide Vaccine for Tumor Revenue (2021-2026)
  2. 3.2 Global Top Players by Peptide Vaccine for Tumor Sales (2021-2026)
  3. 3.3 Global Top Players by Peptide Vaccine for Tumor Price (2021-2026)
  4. 3.4 Global Peptide Vaccine for Tumor Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide Vaccine for Tumor Major Company Production Sites & Headquarters
  6. 3.6 Global Peptide Vaccine for Tumor Company, Product Type & Application
  7. 3.7 Global Peptide Vaccine for Tumor Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide Vaccine for Tumor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide Vaccine for Tumor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide Vaccine for Tumor Tier 1, Tier 2, and Tier 3
4 Peptide Vaccine for Tumor Regional Status and Outlook
  1. 4.1 Global Peptide Vaccine for Tumor Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Peptide Vaccine for Tumor Historic Market Size by Region
  3. 4.2.1 Global Peptide Vaccine for Tumor Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Peptide Vaccine for Tumor Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Peptide Vaccine for Tumor Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Peptide Vaccine for Tumor Forecasted Market Size by Region
  7. 4.3.1 Global Peptide Vaccine for Tumor Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Peptide Vaccine for Tumor Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Peptide Vaccine for Tumor Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Peptide Vaccine for Tumor by Application
  1. 5.1 Peptide Vaccine for Tumor Market by Application
  2. 5.1.1 Infectious Disease Prevention
  3. 5.1.2 Cancer Immunotherapy
  4. 5.1.3 Others
  5. 5.2 Global Peptide Vaccine for Tumor Market Size by Application
  6. 5.2.1 Global Peptide Vaccine for Tumor Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Peptide Vaccine for Tumor Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Peptide Vaccine for Tumor Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Peptide Vaccine for Tumor Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Peptide Vaccine for Tumor Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Peptide Vaccine for Tumor Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Peptide Vaccine for Tumor Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Peptide Vaccine for Tumor Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AmbioPharm
  2. 6.1.1 AmbioPharm Company Information
  3. 6.1.2 AmbioPharm Business Overview
  4. 6.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AmbioPharm Peptide Vaccine for Tumor Product Portfolio
  6. 6.1.5 AmbioPharm Recent Developments
  7. 6.2 Ultimovacs
  8. 6.2.1 Ultimovacs Company Information
  9. 6.2.2 Ultimovacs Business Overview
  10. 6.2.3 Ultimovacs Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Ultimovacs Peptide Vaccine for Tumor Product Portfolio
  12. 6.2.5 Ultimovacs Recent Developments
  13. 6.3 Sellas Life Sciences
  14. 6.3.1 Sellas Life Sciences Company Information
  15. 6.3.2 Sellas Life Sciences Business Overview
  16. 6.3.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio
  18. 6.3.5 Sellas Life Sciences Recent Developments
  19. 6.4 OncoPep
  20. 6.4.1 OncoPep Company Information
  21. 6.4.2 OncoPep Business Overview
  22. 6.4.3 OncoPep Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 OncoPep Peptide Vaccine for Tumor Product Portfolio
  24. 6.4.5 OncoPep Recent Developments
  25. 6.5 Marker Therapeutics, Inc.
  26. 6.5.1 Marker Therapeutics, Inc. Company Information
  27. 6.5.2 Marker Therapeutics, Inc. Business Overview
  28. 6.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio
  30. 6.5.5 Marker Therapeutics, Inc. Recent Developments
  31. 6.6 Immatics
  32. 6.6.1 Immatics Company Information
  33. 6.6.2 Immatics Business Overview
  34. 6.6.3 Immatics Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Immatics Peptide Vaccine for Tumor Product Portfolio
  36. 6.6.5 Immatics Recent Developments
  37. 6.7 Anergis
  38. 6.7.1 Anergis Company Information
  39. 6.7.2 Anergis Business Overview
  40. 6.7.3 Anergis Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Anergis Peptide Vaccine for Tumor Product Portfolio
  42. 6.7.5 Anergis Recent Developments
  43. 6.8 Almac
  44. 6.8.1 Almac Company Information
  45. 6.8.2 Almac Business Overview
  46. 6.8.3 Almac Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Almac Peptide Vaccine for Tumor Product Portfolio
  48. 6.8.5 Almac Recent Developments
  49. 6.9 ACT
  50. 6.9.1 ACT Company Information
  51. 6.9.2 ACT Business Overview
  52. 6.9.3 ACT Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 ACT Peptide Vaccine for Tumor Product Portfolio
  54. 6.9.5 ACT Recent Developments
7 North America by Country
  1. 7.1 North America Peptide Vaccine for Tumor Sales by Country
  2. 7.1.1 North America Peptide Vaccine for Tumor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Peptide Vaccine for Tumor Sales by Country (2021-2026)
  4. 7.1.3 North America Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032)
  5. 7.2 North America Peptide Vaccine for Tumor Market Size by Country
  6. 7.2.1 North America Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Peptide Vaccine for Tumor Market Size by Country (2021-2026)
  8. 7.2.3 North America Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Peptide Vaccine for Tumor Sales by Country
  2. 8.1.1 Europe Peptide Vaccine for Tumor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Peptide Vaccine for Tumor Sales by Country (2021-2026)
  4. 8.1.3 Europe Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Peptide Vaccine for Tumor Market Size by Country
  6. 8.2.1 Europe Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Peptide Vaccine for Tumor Market Size by Country (2021-2026)
  8. 8.2.3 Europe Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Peptide Vaccine for Tumor Sales by Country
  2. 9.1.1 Asia-Pacific Peptide Vaccine for Tumor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Peptide Vaccine for Tumor Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Peptide Vaccine for Tumor Market Size by Country
  6. 9.2.1 Asia-Pacific Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Peptide Vaccine for Tumor Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Peptide Vaccine for Tumor Sales by Country
  2. 10.1.1 South America Peptide Vaccine for Tumor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Peptide Vaccine for Tumor Sales by Country (2021-2026)
  4. 10.1.3 South America Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032)
  5. 10.2 South America Peptide Vaccine for Tumor Market Size by Country
  6. 10.2.1 South America Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Peptide Vaccine for Tumor Market Size by Country (2021-2026)
  8. 10.2.3 South America Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Peptide Vaccine for Tumor Sales by Country
  2. 11.1.1 Middle East and Africa Peptide Vaccine for Tumor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Peptide Vaccine for Tumor Market Size by Country
  6. 11.2.1 Middle East and Africa Peptide Vaccine for Tumor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Peptide Vaccine for Tumor Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Peptide Vaccine for Tumor Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Peptide Vaccine for Tumor Value Chain Analysis
  2. 12.1.1 Peptide Vaccine for Tumor Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Peptide Vaccine for Tumor Production Mode & Process
  7. 12.2 Peptide Vaccine for Tumor Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Peptide Vaccine for Tumor Distributors
  10. 12.2.3 Peptide Vaccine for Tumor Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst